TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer
- Connolly, R. M.
- Leal, J. P.
- Goetz, M. P.
- Zhang, Z.
- Zhou, X. C.
- Jacobs, L. K.
- Mhlanga, J.
- O, J. H.
- Carpenter, J.
- Storniolo, A. M.
- Watkins, S.
- Fetting, J. H.
- Miller, R. S.
- Sideras, K.
- Jeter, S. C.
- Walsh, B.
- Powers, P.
- Zorzi, J.
- Boughey, J. C.
- Davidson, N. E.
- Carey, L. A.
- Wolff, A. C.
- Khouri, N.
- Gabrielson, E.
- Wahl, R. L.
- Stearns, V.
Publication date
January 2015
DOIAbstract
Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neo-adjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in women with stage II/III, human epidermal growth factor receptor 2 (HER2)–negative breast cancer, in which we also examined whether change in maximum standardized uptake values corrected for lean body mass (SULmax) on 18F-FDG PET predicted pathologic complete response (pCR) in breast and axillary lymph nodes
Add to ORKG